The Top 5 Biosimilars Articles for the Week of January 6

The Center for Biosimilars® recaps the top stories for the week of January 6.
 
January 11, 2020


Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of January 6, 2019.

Number 5: A recent study finds that peer influence factors heavily into whether oncologists decide to adopt bevacizumab for their patients.

Number 4: The FDA notes the approval of 10 biosimilars in its 2019 report of drug approvals, which included 48 novel drugs.

Number 3: A look back at the top 5 legal stories in 2019 finds that cases involving adalimumab featured in 2 of them.

Number 2: Novo Nordisk takes 3 steps to improve insulin affordability, and says the FDA expanded use of its fast-acting mealtime insulin to children as young as 2.

Number 1: Pfizer says it is launching its bevacizumab biosimilar, Zirabev, in the United States.

To read all of these articles and more, visit centerforbiosimilars.com.
 

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.